ADAURA, Explosion of Targeted Agents Underscore Need for Molecular Testing in Lung Cancer

June 15th 2021

Courtney Marabella

The data from the phase 3 ADAURA trial with adjuvant osimertinib are among the most significant to read out in the past year in the realm of non–small cell lung cancer.

Iomab-B Continues to Showcase Impressive Bone Marrow Transplant and Engraftment Rate in Relapsed/Refractory AML

June 15th 2021

Gina Mauro

Iodoine apamistamab, a radiotherapy that targets CD45-expressing cells, demonstrated a 100% bone marrow transplant and engraftment rate in patients with relapsed/refractory acute myeloid leukemia vs 18% for those who received a physician’s choice of salvage treatment.

Investigators Set Sights on Curative Approaches for Follicular Lymphoma

June 15th 2021

Christina Loguidice

The majority of patients with indolent follicular lymphoma do well with observation and after first-line treatment, but approximately 20% experience disease progression within 2 years of their initial treatment, which is associated with a 50% risk of dying within 5 years. Subsequently, this is an area of unmet need but one in which considerable progress is being made.

Novel Targets Set to Add to Checkpoint Blockade Success in Merkel Cell Carcinoma

June 15th 2021

Jessica Hergert

James A. DeCaprio, MD, discusses the incidence of Merkel cell carcinoma, risk factors for the disease, established treatment options, and investigational regimens on the horizon.

Upcoming Live Broadcast to Feature Recent Data and Case Study in ALK+ Metastatic NSCLC

June 15th 2021

As the treatment landscape for ALK-positive metastatic non-small cell lung cancer continues to take shape, extended analyses of clinical trial data may offer additional clinical insight on the utility of approved therapies.